Comparing the effects of Berberine, Curcumine and gonadotropin-releasing hormone agonist (GnRH) on uterine leiomyoma volume
- Conditions
- terine myoma.
- Registration Number
- IRCT20220201053908N1
- Lead Sponsor
- Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 102
Non-menopausal women between the ages of 18 and 45, who have a myoma larger than 5 cm that have abnormal uterine bleeding, pelvic pain, dysmenorrhea, and a compressive effect.
Women with myomas larger than or equal to 5 cm who have other myomas (s) less than 2 cm in size
Women with extra myoma (s) greater than or equal to 2 cm
Women with uterine myoma who have been treated with any type of estrogen or progesterone in less than a month and hormonal implants in the last 3 months
Women with a history of major medical illness and / or previous drug or surgical treatment of uterine leiomyomas
All women with myomas 2-5 cm in size were excluded from the study
Patients receiving antihypertensive drugs, beta-blockers and calcium channel blockers, and ACE inhibitors were excluded from the study due to possible drug interactions
Patients who develop side effects during the study will be excluded from the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method terine myoma size. Timepoint: At the beginning of the study and 6 and 12 weeks after starting treatment. Method of measurement: Vaginal ultrasound machine.
- Secondary Outcome Measures
Name Time Method H hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.;FSH hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.;Estradiol hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.